A new FGF1 variant protects against adriamycin-induced cardiotoxicity via modulating p53 activity

A cumulative and progressively developing cardiomyopathy induced by adriamycin (ADR)-based chemotherapy is a major obstacle for its clinical application. However, there is a lack of safe and effective method to protect against ADR-induced cardiotoxicity. Here, we found that mRNA and protein levels o...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Mengjie, Tang, Yufeng, Wang, Jie, Lu, Guangping, Niu, Jianlou, Li, Jiahao, Liu, Qingbo, Wang, Zhaoyun, Huang, Zhifeng, Guo, Yuanfang, Gao, Ting, Zhang, Xiaohui, Yue, Shouwei, Gu, Junlian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743227/
https://www.ncbi.nlm.nih.gov/pubmed/34990928
http://dx.doi.org/10.1016/j.redox.2021.102219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743227/
https://www.ncbi.nlm.nih.gov/pubmed/34990928
http://dx.doi.org/10.1016/j.redox.2021.102219

Ejemplares similares